Neuroscientists at Georgetown University Medical Center (GUMC), USA and Germany’s Technische Universität München say they have uncovered the brain malady responsible for tinnitus and for chronic pain.
University of Florida Health researchers have uncovered more evidence of a link between the brain’s stress response and a protein related to Alzheimer’s disease.
Hailed as a "breakthrough" treatment for people suffering from the effects of traumatic brain injury (TBI), researchers have found a unique method of applying high-powered near-infrared light (NIR) that can penetrate the skin and skull to reach the damaged portions of the brain, and effectively accelerate regeneration of the brain cells’ functionality with minimal skin irritation.
Medtronic plc has announced the US launch of the Arc support catheter, the most navigable, 6F tapered support catheter available. Developed to improve delivery of Medtronic’s Solitaire stent retriever, the Arc support catheter provides the fastest route to restoration of blood flow in patients with complex anatomy suffering acute ischaemic stroke. The Arc catheter series received US Food and Drug Administration 510(K) clearance in July 2015.
Intense medical research and technology development have recently produced powerful new techniques to treat acute ischaemic stroke. The positive results of multiple randomised thrombectomy trials (including MR CLEAN, EXTEND-IA, ESCAPE, SWIFT PRIME, and REVASCAT) have revolutionised the management of this devastating condition and generated a sudden increase in demand for properly equipped institutions and trained personnel.
Phenox GmbH has announced the start of the pToWin study after enrolling the first patient on 2 September, 2015. The prospective, multicentre, single-arm study pToWin (pCONus treatment of wide neck intracranial aneurysms) aims to assess safety and efficacy of the pCONus bifurcation aneurysm implant.
Researchers may have discovered a new marker found in the blood for episodic migraine, according to a study published in the online issue of Neurology, the medical journal of the American Academy of Neurology. Episodic migraine is defined as having less than 15 headaches per month.
Boston Scientific has received CE mark for the Vercise primary cell deep brain stimulation system. The Vercise system is intended to provide precise neural targeting to address the varying needs of patients suffering from Parkinson’s disease, primary and secondary dystonia, and essential tremor. The system is a non-rechargeable treatment option that also powers the Vercise deep brain stimulation Directional Lead, the first commercially available eight-contact segmented lead with current steering.
The first patients to benefit from Flowonix Medical’s newly Food and Drug Administration-approved Patient Therapy Controller (PTC) have received the device. W Porter McRoberts in Fort Lauderdale, USA, and Daniel R Kloster in Kansas City, USA, were among the first to prescribe the state-of-the-art device for their chronic pain patients who use the Prometra implantable drug infusion system.
Penumbra has announced that the company’s ACE64 aspiration thrombectomy system received 510(k) marketing clearance from the US Food and Drug Administration for the revascularisation of large vessel occlusions in patients with acute ischaemic stroke.
In 2009 I became president of the International Neuromodulation Society (INS). I realised then that the INS had to brand the term neuromodulation in order to support the broad acceptance of a diverse range of neurostimulation therapies within the dogma of medical practice and wider health economy. The three biennial congresses that followed in London 2011, Berlin 2013 and Montreal 2015 each had a strap line that were written in the present tense and linked innovative technological medicine with chronic disease management and care that put patients at the centre of their care: “Technology that Improves Patient Care”, “Technology Transforming Chronic Illness Management”, and “Medicine evolving through Technology”. These phrases also capture the sense that medical practice and our understanding of disease management is changing and will change more.
Recently no less than five randomised controlled trials showed superiority for intra-arterial treatment added to intravenous thrombolysis (IVT) of large artery stroke in the anterior circulation as compared to stand-alone IVT1–5. This obvious breakthrough is more than welcomed, but it is also clear from these studies that challenges remain, not least for the neurointerventionalists. In all the studies, the revascularisation percentage was far from 100% (Figure 1); sometimes it is quite impossible to remove the thrombus in a safe and efficient way. Further, even if perfect revascularisation is achieved, the percentage of patients having a good outcome is much less. Such so-called futile revascularisation has probably many reasons, but one of them may be a prolonged procedure time.
To conduct the analysis, investigators from both trials assessed the effect of endovascular treatment in acute ischaemic stroke patients with severe neurological deficit (National Institutes of Health Stroke Scale [NIHSS] score, ≥20) after a prespecified analysis plan.
Stent retriever technology has been named by the Cleveland Clinic as a top medical innovation. It was part of a list of the top medical innovations for 2015, revealed at the Cleveland Clinic’s 2015 Medical Innovation
Blockade Medical LLC has announced the closing of a round of equity financing. The financing was comprised of existing investors and new investment from TitanMed Capital and GP Healthcare Capital, venture capital and private equity funds, which are dedicated to healthcare investments. The company also announced the formation of a joint venture for future manufacturing of Blockade devices for the Chinese marketplace.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos